Patent · US Active

Crystalline forms OF N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide

US12252479B2 · kind B2 · utility

0Cited by

1References

12Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Stephanie Kay Dodd · Ayer, US
Arnaud GRANDEURY · Helfrantzkirch, FR
Emmanuel Suffert · Basel, CH
Evgenia Rousaki · Basel, CH

Key dates

Filing date	Jul 6, 2022
Grant date	Mar 18, 2025
Priority date	—
Expiry date	Jul 9, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention describes specific crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide. The present invention further relates to methods for preparing said crystalline forms, pharmaceutical compositions comprising said crystalline forms, and methods of using said crystalline forms and pharmaceutical compositions to treat disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.